AU2021381360A1 - Method for treating antibody-mediated rejection - Google Patents

Method for treating antibody-mediated rejection Download PDF

Info

Publication number
AU2021381360A1
AU2021381360A1 AU2021381360A AU2021381360A AU2021381360A1 AU 2021381360 A1 AU2021381360 A1 AU 2021381360A1 AU 2021381360 A AU2021381360 A AU 2021381360A AU 2021381360 A AU2021381360 A AU 2021381360A AU 2021381360 A1 AU2021381360 A1 AU 2021381360A1
Authority
AU
Australia
Prior art keywords
inh
administered
doses
recipient
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021381360A
Other languages
English (en)
Inventor
John Roberts
Marc UKNIS
Christine VOIGT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of AU2021381360A1 publication Critical patent/AU2021381360A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2021381360A 2020-11-20 2021-11-18 Method for treating antibody-mediated rejection Pending AU2021381360A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063116405P 2020-11-20 2020-11-20
US63/116,405 2020-11-20
PCT/US2021/059872 WO2022109124A1 (en) 2020-11-20 2021-11-18 Method for treating antibody-mediated rejection

Publications (1)

Publication Number Publication Date
AU2021381360A1 true AU2021381360A1 (en) 2023-06-22

Family

ID=78918649

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021381360A Pending AU2021381360A1 (en) 2020-11-20 2021-11-18 Method for treating antibody-mediated rejection

Country Status (8)

Country Link
US (1) US20240000908A1 (https=)
EP (1) EP4247416A1 (https=)
JP (1) JP2023551193A (https=)
KR (1) KR20230110563A (https=)
CN (1) CN116568327A (https=)
AU (1) AU2021381360A1 (https=)
CA (1) CA3198740A1 (https=)
WO (1) WO2022109124A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025067383A1 (zh) * 2023-09-28 2025-04-03 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗抗体介导性排斥反应的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
DE69534265T2 (de) 1994-12-12 2006-05-04 Beth Israel Deaconess Medical Center, Inc., Boston Chimäre zytokine und ihre verwendung
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7053176B1 (en) 1999-09-16 2006-05-30 Altana Pharma Ag Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
CA2678001C (en) 2007-02-12 2017-07-11 Stefan Schulte Therapeutic application of kazal-type serine protease inhibitors
EP4162947A1 (en) 2013-11-22 2023-04-12 Takeda Pharmaceutical Company Limited Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
US20190175683A1 (en) * 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor

Also Published As

Publication number Publication date
JP2023551193A (ja) 2023-12-07
CN116568327A (zh) 2023-08-08
KR20230110563A (ko) 2023-07-24
EP4247416A1 (en) 2023-09-27
WO2022109124A1 (en) 2022-05-27
CA3198740A1 (en) 2022-05-27
US20240000908A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
JP5722524B2 (ja) 補体活性を抑制することによる同種移植片の生存の延長
US9044436B2 (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
JP5590624B2 (ja) 補体活性を阻害することによる同種移植片の生存の延長
US20090092602A1 (en) Use of anti-tissue factor antibodies for treating thromboses
JP6620206B2 (ja) 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法
BG64841B1 (bg) Използване на анти-сd40l(анти-сd154) антитяло илипроизводно на антитяло за предпазване на приспособимите към противопоставяне имунни отговори, по-специално при отхвърляне на трансплантант
Myburgh et al. Total lymphoid irradiation in renal transplantation
US20240000908A1 (en) Method for Treating Antibody-Mediated Rejection
Guo et al. Long‐term survival of intestinal allografts induced by costimulation blockade, busulfan and donor bone marrow infusion
EP1240904B1 (de) Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstossung von Xenotransplantaten in Säugetieren
WO2022161484A1 (en) Methods of treating chronic active antibody-mediated rejection using btk inhibitors
TWI886139B (zh) 藉由使用抗c5抗體克羅伐單抗（crovalimab）之治療或預防c5相關疾病之劑量及投藥療程
Warren et al. Modulating alloimmune responses with plasmapheresis and IVIG
US20140309167A1 (en) Combination of active ingredients for the treatment of acute kidney injury
Jarmoliński et al. Short course of eculizumab may be effective in dialysis-dependent transplantation-associated thrombotic microangiopathy after hematopoietic stem cell transplantation: a case report
US20240424055A1 (en) Administration of c5-binding proteins
JPH10504310A (ja) 生物学的に活性な化合物で患者を治療する方法
Kumar et al. Antilymphocyte Globulin (ALG) infusion in the treatment of acute renal allograft rejection: a prospective study
Habal et al. Renal allografting in the patient with juvenile diabetes mellitus
CN118973600A (zh) 用于脐带血移植后的血细胞恢复的药物组合物
Kobayashi et al. Prolongation of Xenograft Survival by Cobra Venom Factor
Neira et al. Cyclosporine A in five children with severe aplastic anemia
INTEREST—PHASE III Pharmaceutical Clinical Trials—Phase Three
HK1240072A1 (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor